Feb 3, 2020 - Health

Clinical trial for HIV vaccine ends in failure

The experimental vaccine against the AIDS virus for the 2016 clinical trial. Photo: Mujahid Safodien/AFP via Getty Images

A vaccine aimed at preventing the human immunodeficiency virus (HIV) has failed and will end its clinical trial in South Africa early, according to the National Institute of Allergy and Infectious Diseases.

Why it matters: About 34 million people are living with HIV/AIDS globally, according to 2018 data from the World Health Organization. South Africa has one of the highest HIV rates in the world, with young women especially at risk.

"An HIV vaccine is essential to end the global pandemic, and we hoped this vaccine candidate would work. Regrettably, it does not. Research continues on other approaches to a safe and effective HIV vaccine, which I still believe can be achieved."
ā€” Anthony Fauci, director of the NIAID, said in a written statement on Monday

Details: The trial, sponsored by NIAID, began in 2016 with 5,407 HIV-negative volunteers across South Africa and was supposed to end in July 2022.

  • 129 HIV infections occurred among the vaccine recipients, and 123 HIV infections occurred among the placebo recipients.
  • There is no evidence that the vaccine caused harm, NIAID said.
  • The Global HIV Vaccine Enterprise expressed "deep disappointment" in learning the trial was ending, according to a statement.

What's next: Two late-stage, multinational HIV vaccine trials are still being conducted by the National Institutes of Health.

Go deeper: HIV-positive babies could benefit from treatment days after birth

Go deeper

New testing for coronavirus emerges from MERS, Ebola anti-virals

MERs is in the same family as the novel coronavirus which began to infect patients in Wuhan, China. Photo: Smith Collection/Gado/Getty Images

Scientists and doctors are exploring whether existing treatments for HIV, Ebola and malaria could combat the coronavirus, the Los Angeles Times reports.

Driving the news: The antiviral remdesivir protected monkeys from MERS, another coronavirus, both before and after exposure, the National Institute of Health announced Thursday.

Go deeperArrowFeb 14, 2020 - Health

Vaccine candidate for coronavirus on track for human trials in April

A scientist is at work in the VirPath university laboratory as they try to find an effective treatment against 2019-nCoV. Photo: Jeff Pachoud/AFP via Getty Images

The National Institutes of Health and biotech company Moderna, one of several companies working to develop treatment for the novel coronavirus, are on track for human clinical trials for a vaccine in two and half months, National Institute of Allergy and Infectious Diseases director Anthony Fauci, said in a press briefing Friday.

Why it matters: If the trials prove effective, the vaccine could help protect people from future outbreaks. The researchers were able to successfully take the virus's genetic code and express proteins for animal trials. ā€œIā€™m happy to tell you there are no glitches so far," Fauci said.

Go deeper: Billionaires and multinationals donate to fight coronavirus

Rural communities face HIV outbreak risk due to lack of syringe exchanges

Illustration: Sarah Grillo/Axios

Rural communities at risk of HIV outbreaks tied to drug use often don't have working syringe exchanges, which help reduce the spread of HIV and Hepatitis C, NPR reports with Kaiser Health News.

Between the lines: Many of these rural communities have seen local opposition against syringe exchanges, which provide drug users with clean needles.

Go deeperArrowFeb 18, 2020 - Health